Denmark to play a central role in EU cooperation on medicines

19 November 2026

From 8 December, the Danish Medicines Agency will take up the post of CMDh vice-chair. This will give Denmark a central role in European cooperation on the authorisation of medicines for human use.

The Danish Medicines Agency has secured a new role in the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh).

The group, which comprises representatives from all EU Member States, has elected Katrine Damkjær Madsen, one of the Danish Medicines Agency’s regulatory experts, as its new vice-chair with effect from 8 December 2026.

The appointment is a significant achievement for the Danish Medicines Agency and strengthens Denmark’s standing in Europe.

‘As vice-chair, Denmark can do even more to help build consensus and ensure consistency when medicines for human use are authorised in two or more European countries at the same time. We will take an active role in shaping cooperation among EU countries so that it brings the greatest possible benefits to Denmark, the EU and patients,’ says Hanne Lomholt Larsen, Head of Regulatory and Clinical Evaluation at the Danish Medicines Agency. She adds:

‘The CMDh ensures that medicines authorised at national level are handled consistently across countries. It does this by establishing common procedures so that countries apply the legislation consistently. This matters because these are the medicines that people across the EU use most widely. The group’s work improves predictability and, in turn, helps make medicines more readily available to people in Denmark and across Europe.’

Katrine Damkjær Madsen has been Denmark’s representative on the CMDh since 2013 and has been elected vice-chair for a three-year term.

The appointment gives Denmark a central role in European cooperation on medicines and a greater opportunity to bring Danish perspectives to the development of regulatory cooperation among EU Member States.

A strong life sciences sector and the patients of tomorrow

The work of the CMDh matters to patients and the life sciences sector across Europe. For example, the group’s Member States work together to coordinate authorisation procedures for new medicines, variations to existing marketing authorisations and initiatives to monitor the safety of medicines. The group’s work focuses in particular on regulatory issues involving generic medicines for which marketing authorisation has been sought or granted in two or more European countries.

‘The CMDh helps European countries work together effectively so that patients have equal access to safe and effective medicines wherever they live. Its work also supports a strong life sciences sector by helping to put in place the regulatory framework for future medicines and treatments,’ says Hanne Lomholt Larsen.

Katrine Damkjær Madsen succeeds Susanne Winterscheid of Germany’s Federal Institute for Drugs and Medical Devices (BfArM) as vice-chair.

Katrine Damkjær Madsen is a qualified pharmacist and has worked on regulatory procedures in the EU and Denmark for more than 20 years.

Link

Read more about the CMDh (hma.eu)